Stryker Corporation $SYK Shares Acquired by CW Advisors LLC

Key Points

• CW Advisors LLC increased its holdings in Stryker Corporation by 18.5% in Q1, owning 61,118 shares valued at approximately $22.76 million.
• Stryker reported earnings of $3.13 per share for the last quarter, surpassing estimates, with an 11.1% year-over-year revenue increase to $6.02 billion.
• The company recently declared a quarterly dividend of $0.84, equivalent to an annualized yield of 0.9%, with a current payout ratio of 44.50%.

CW Advisors LLC grew its stake in Stryker Corporation (NYSE:SYK - Free Report) by 18.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,118 shares of the medical technology company's stock after acquiring an additional 9,529 shares during the quarter. CW Advisors LLC's holdings in Stryker were worth $22,759,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Elefante Mark B purchased a new position in Stryker during the 4th quarter worth $337,000. Mogy Joel R Investment Counsel Inc. grew its stake in Stryker by 3.4% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after buying an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. grew its stake in Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after buying an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new position in Stryker during the 1st quarter worth $1,840,000. Finally, Mar Vista Investment Partners LLC grew its stake in Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after buying an additional 8,353 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SYK. BTIG Research restated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Citigroup restated a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Needham & Company LLC boosted their price target on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Truist Financial set a $415.00 price target on Stryker and gave the company a "hold" rating in a research note on Monday, August 4th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $430.10.

Stryker Stock Performance

Stryker stock traded up $8.9740 during trading hours on Friday, hitting $393.8040. 896,076 shares of the stock traded hands, compared to its average volume of 1,348,874. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm's 50 day moving average price is $387.51 and its 200-day moving average price is $379.37. The stock has a market capitalization of $150.56 billion, a price-to-earnings ratio of 52.16, a P/E/G ratio of 2.86 and a beta of 0.91. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's payout ratio is 44.50%.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.